J

Jung‐Yun Lee

Yonsei University

ORCID: 0000-0001-7948-1350

Publishes on Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, PARP inhibition in cancer therapy. 593 papers and 8.2k citations.

PubIndex Score78Top 22% · seniorHow it's scored

593Publications

8.2kTotal Citations

First publication: 1990First senior author: 2006

Ovarian cancer diagnosis and treatment Endometrial and Cervical Cancer Treatments PARP inhibition in cancer therapy Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics

Top publicationsby citations

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Funda Meric‐Bernstam, Jung‐Yun Lee|Journal of Clinical Oncology|2023

Cited by 882

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

Paul A. Cohen, Arjun Jeyarajah, Gustavo Rubino de Azevedo Focchi et al.|Gynecologic Oncology|2019

Cited by 121

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer

Panagiotis A. Konstantinopoulos, Ronnie Shapira‐Frommer, Jungmin Lee et al.|Gynecologic Oncology|2022

Cited by 66

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies

Rowan Miller, Jung‐Yun Lee, Karim El-Shakankery|Journal of Gynecologic Oncology|2022

Cited by 54

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

Kathleen N. Moore, Toon Van Gorp, Antoine Angelergues et al.|Journal of Clinical Oncology|2023

Cited by 53